A June 2026 review of antiandrogens, treatments that lower androgen-driven oil-gland activity, found lesion drops with spironolactone and metformin, not a new cure. Adults with persistent breakouts should treat the headline as early evidence and check fit, limits, and safety before acting. The review covered 13 studies and called for stronger efficacy and safety trials, according to Actas Dermo-Sifiliográficas, in the June 2026 review PDF. That call means the result guides discussion, not self-treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the review tested and what it did not
- Where spironolactone fits in current care
- Does jawline acne mean hormones are the cause?
- What should you clarify before starting?
- How can you avoid overreading the next headline?
What the review tested and what it did not
The same review grouped spironolactone studies separately from metformin studies and tracked lesion drops. It listed no eligible bicalutamide studies for adult female acne.
That matters because a missing drug is not a verdict on that drug. Lesion drops do not equal clearance, and small study pools leave safety questions open. Read the result as a signal to discuss, not a reason to switch care alone.
Where spironolactone fits in current care
Current American Academy of Dermatology guidance gives strong backing to benzoyl peroxide, retinoids, combos, and isotretinoin for severe disease. Spironolactone, clascoterone, and combined oral contraceptives are conditional, case-by-case options, per the same guidance in Dermatology Times guideline summary.
If topicals are working, a headline alone does not make a systemic drug the next step. If breakouts persist, ask where hormonal options sit among other choices for your case.
Does jawline acne mean hormones are the cause?
Cutis notes jawline pattern does not predict high androgens or PCOS, and these drugs work across sexes and ages, in Cutis practical guide. Location alone should not decide who gets these drugs.
Do not rule yourself in or out by chin pattern alone. Use history, exam, and clinician judgment instead of mirror mapping.
What should you clarify before starting?
Clinician.com notes off-label acne dosing is often 50-100 mg within a 50-200 mg daily range. It warns the drug is contraindicated in pregnancy for feminization risk to a male fetus, so reliable contraception is required, in Clinician.com spironolactone review.
Use these points to prepare for the visit: Bring a full drug and supplement list to the visit. Ask what to stop or continue if side effects appear.
- what you use now and what failed
- pregnancy plans and contraception
- other health issues and drugs you take
- how and when to follow up
How can you avoid overreading the next headline?
Check who was studied, how many, for how long, and against what. Look for absolute change and safety follow-up, not only percent drops.
See whether guidelines list the option as strong or case-by-case. Save the study name and month when you see a claim. Bring that note to your visit and ask where you fit in the evidence.
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Limited Topical Spironolactone Evidence in the 2026 Review: How Adults With Persistent Acne Can Avoid Overreading the Headline
- Topical Clascoterone Evidence Revisited in 2026: How Adults With Persistent Acne Can Avoid Overreading the Headline